Peptides: where the money actually is

Every pool below is measured the same way: annual revenue, 2026. Where sources disagree I show both numbers rather than picking the flattering one. Where a source is a company selling into the market it describes, I say so — those figures are marketing, not accounting.

The pools are ordered largest to smallest, which is also roughly the order of how hard they are to reach with no capital. That tension is the whole report.

Two companies own the actual peptide economy. This is the gravity well everything else orbits.

Tirzepatide is projected to be the single best-selling drug in the world in 2026 at over $45B. Lilly has overtaken Novo in the US; Zepbound now outsells Wegovy on prescriptions.

Legal businesses, thousands of them, mostly small and owner-operated. They buy from licensed channels, they have real premises, and they are not going to be indicted.

Peptide therapy consultations are the fastest-growing longevity service at med spas in 2026. That is the sentence to build a business on. These clinics want peptide revenue, and they are not sophisticated buyers of software, marketing, or compliance paperwork.

The cautionary tale. Hims & Hers rode compounded GLP‑1s from $1.5B (2024) to $2.35B (2025) revenue, then hit the wall.

• Q1 2026 revenue $608.1M, up only 4% YoY — and missed estimates.
• Surprise net loss of $92.1M, plus $33.5M in restructuring charges, from pivoting off compounded product to branded.
• Subscribers ~2.6M, up 9%. Full-year guidance raised to $2.8–3.0B.
• Referred to the DOJ on 6 February 2026 for potential federal violations.

A public company with lawyers and $2B+ of revenue could not keep the compounding model. That is the clearest available signal about what happens to smaller operators doing the same thing.

The genuine picks-and-shovels layer — and the smart money is piling into it right now.

• PolyPeptide: $444M revenue in 2025, up 15.6%, driven by GLP‑1s. Guiding to +20–25% in 2026.
• Samsung Biologics is paying $1.8B to buy into peptide manufacturing.
• Bachem is investing over $615M in a new Swiss production site — commercial output not until 2030.
• North American peptide CDMO capacity expansion hit a five-year high in 2026.

Traceable crypto inflows to gray-market peptide vendors, which is the best proxy anyone has for the size of this thing.

Roughly 100× growth in two years. On the surface that is the most exciting number in this document. Three things gut it:

1. The biggest players are being removed

PeptideSciences.com was doing over $7M per month at peak. It shut down in early March 2026. Paradigm Peptides' operators were federally charged in February 2026.

2. The supply chain is genuinely dirty

Two Chinese manufacturers now selling peptides — Shanghai Sigma Audley and Bigreat Technology — were previously identified as fentanyl and amphetamine precursor suppliers to cartels and darknet vendors, and rebranded into peptides. One had processed $3.59M in stablecoins and taken $130K directly from darknet drug vendors.

3. Buyers stopped caring about quality

As the market went mainstream, third-party testing spend fell to $8 per buyer — an 88% decline. Meanwhile at least two Brooklyn bodegas were found selling peptide vials over the counter with no age check and no prescription.

Here is the honest correction to what I told you earlier. I said the whole testing market was “a few million split eight ways.” The leader alone is bigger than that: Janoshik's crypto inflows grew from $187K to $502K per month, about $6M/year, with $12M received cumulatively since 2023. It is a real business.

It is also the most competitive square inch of this entire map, and the domestic gap we planned to lead with is not there.

The real gap, which is not a lab

Fake certificates are rampant and documented: vendors steal real COAs and swap the logo, generate template COAs with no batch data, and now use AI to fabricate chromatograms — the tell is peaks that are unnaturally symmetrical. Labs have publicly confirmed that certificates attributed to them were forged. There is no mandatory COA standard, no auditor, and no penalty for fabrication.

Verification of certificates is a data and reputation problem, not an instrument problem. Finnrick already occupies that position. Note also what it implies: the moat is published history, and the counter is that buyers who stopped paying $8 for a test are unlikely to pay for a verification service either.

This is the section that decides everything. The relevant statutes are 21 USC 331(b) (misbranding) and 21 USC 331(d) (unapproved new drug).

• Dec 2024FDA warning letters to five companies over unapproved GLP‑1 products including retatrutide.
• Feb 2025Warning letter to USApeptide.com. FDA states plainly that “research use only” labelling is not a defence where evidence shows human intent.
• Sep 202555+ warning letters issued.
• Oct 2025Peptide Sciences shut down — one of the largest US vendors.
• Feb 2026FDA moves to restrict GLP‑1 APIs in compounding — choking the supply chain at source. Hims & Hers referred to DOJ.
• Feb 2026Paradigm Peptides operators criminally charged — misbranded drugs, unlicensed pharmacy.
• Mar 202630 warning letters to telehealth companies.
• 30 Apr 2026FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list — closing the last legal pathway for most compounded GLP‑1s.
• Jun 202625 further warning letters.

Alongside this: more than 1,700 adverse events logged against compounded semaglutide and tirzepatide as of May 2026, many from dosing errors.

Call it $120K–200K and eighteen months before the first invoice, to enter a $6M market against a ten-year incumbent, selling to customers under federal investigation, whose willingness to pay for testing has dropped 88%.

The money in peptides is enormous and almost all of it is either locked behind a pharmaceutical licence or behind nine figures of manufacturing capex. The parts a person can enter without either are the parts under criminal enforcement.

With one exception.

On the lab

Don't. Not on evidence this clear. And do not put the original thesis in front of Molly — she is a businessperson and the ten minutes of searching that produced this document is available to her too. Finding Colmaric in Florida after being told there is no domestic option would cost you her confidence permanently, and that is worth more than this deal.

Bringing her this document instead — the one where you killed your own idea on evidence — is a genuinely strong opening move. Very few people can do it, and it's the single most investable thing you can show at fifteen.

Gray-market sizing and vendor crypto flows: Chainalysis, Becker's Hospital Review.
Testing labs: BetterNewLives lab directory, peptideone, ACS Laboratory.
Branded pharma: CNBC, Fierce Pharma, Drug Discovery Trends, eMarketer.
Telehealth: Fierce Healthcare, STAT.
Manufacturing: C&EN, DCAT.
Clinics: Mordor Intelligence, Precedence Research, Research and Markets.
Enforcement: FDA, Orrick, Venable, AMC Defense Law, Stanford Medicine.
Equipment & accreditation: AmpTech, GenTech Scientific, APHL accreditation cost survey, QSE Academy.
COA fraud: Peptigrity, Lone Star.

Caveat: market-sizing reports from commercial research firms are estimates with wide error bars, and several peptide-industry sources cited here sell into the market they describe. Figures sourced to Chainalysis, FDA, company earnings, and law-firm analyses are the load-bearing ones. Anything from a vendor blog is flagged in place.